Sotagliflozin, a drug for diabetes and kidney disease, offers significant protection against heart attacks and strokes by ...

Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart ...

A newly approved drug for type 2 diabetes and kidney disease, sotagliflozin, has shown remarkable benefits in reducing the ...

Less than 5% of hospitalized adults with type 2 diabetes received an SGLT2 inhibitor or GLP-1 before being discharged, ...

Consultant in endocrinology and diabetes Professor Vinod Patel discusses current recommended pharmacological treatment ...

Lexicon (LXRX) announced The Lancet Diabetes & Endocrinology has published a research paper analyzing the ability of sotagliflozin, a dual ...

The deaths are also partly the result of medical successes: People are living longer, and more people are surviving heart ...

The medication, known as sodium-glucose co-transporter 2 inhibitors (SGLT2is), is already used to lower blood sugar in people ...

The results showed that people who took sotagliflozin had a 23% lower risk of heart attacks, strokes, and death from ...

• Glucagon-like peptide 1 receptor agonists (GLP-1) (medicines used to lower blood glucose) probably reduce the risk of death due to any cause but may have little or no death due to a heart attack in ...

Sildenafil was effective for reducing diastolic dysfunction and altered ejection fraction among patients with SSc.

This article showcases a curated list of standout studies over the last week on topics such as cholesterol, GLP-1 drugs for ...